NIH funds a $4 million trial on why weight returns after stopping GLP-1 drugs

Bioengineer.org reported on October 3, 2026, that a UTHealth Houston team has received a five-year, $4 million grant from the National Institutes of Health to study why weight returns after people stop GLP-1 receptor agonist medications ^[1]. The project is led by Absalon Gutierrez, MD, of the Division of Endocrinology, Diabetes, and Metabolism at McGovern Medical School, with Vanderbilt University and the Border Health Research Center in Brownsville as partners ^[1]. The story describes the planned trial's design and aims rather than any findings ^[1].

The problem the trial targets

GLP-1 receptor agonists are drugs that imitate glucagon-like peptide-1, a gut hormone, to reduce appetite and improve metabolic control ^[1]. According to figures the research team cites, roughly 30 percent of patients stop within six months, about 50 percent stop within a year, and most people regain more than 60 percent of the weight they lost within a year of stopping ^[1]. The story attributes these figures to research cited by the UTHealth Houston team ^[1]. Regain varies between patients, which has led the investigators to propose a "metabolic memory": lasting molecular effects of the drug or of the earlier weight loss that keep shaping metabolism after treatment ends ^[1]. The work also addresses weight cycling, described in the report as repeated loss and regain of weight when a pharmacologic, dietary or surgical weight loss strategy is stopped and restarted ^[1].

How the study is designed

• Design: a double-blind randomized trial, with random assignment and blinded conditions ^[1].
• Participants: 100 people with obesity drawn from the Border Health Research Cohort ^[1].
• Intervention: everyone receives semaglutide for six months, after which half are randomly assigned to stop and half continue GLP-1 therapy ^[1].
• Genetic analysis: markers related to insulin metabolism, energy expenditure, appetite hormones and body composition ^[1].
• Tissue and blood: small fat tissue and blood samples to track gene activity, circulating molecules and immune signals after withdrawal ^[1].
• Physiology: a standardized test meal to measure blood sugar, insulin response and appetite, whole-body scans that separate fat loss from muscle loss, and breathing tests of resting calorie burn ^[1].
• Behaviour: surveys of diet and exercise so behavioural factors can be accounted for ^[1].

The cohort comes from Americans of Mexican descent in the Lower Rio Grande Valley, a group the report describes as historically underrepresented in metabolic research despite a substantial burden of cardiometabolic disease ^[1]. The Border Health Research Center was established in 2003 ^[1].

Why it matters to these readers

For adults using or considering medical weight loss, and the clinicians who prescribe it, the report frames weight regain after discontinuation as a major clinical problem ^[1]. The report notes that regained weight brings back risks including type 2 diabetes and cardiovascular complications, and that weight cycling can contribute to muscle loss and slower resting metabolism ^[1]. Those concerns sit close to the work of physician-guided weight loss, rehabilitation and surgical pre-optimization, the services AthleticsMD offers in Columbia and Laurel/Fort Meade, Maryland ^{[AthleticsMD]}. Readers weighing a GLP-1 medication should talk with a clinician about their own situation ^{[AthleticsMD]}.

What to watch

• Timing: the grant runs five years, and the story describes planned work rather than results ^[1].
• Prediction: whether the candidate markers can tell clinicians early which patients are likely to regain weight and which might taper off therapy ^[1].
• Novelty: co-principal investigator Joseph B. McCormick, MD, said controlled molecular studies of GLP-1 receptor agonist exposure and withdrawal have not previously been reported, and that the trial could identify new drug targets and predictive biomarkers ^[1].
• Scope: the trial enrolls 100 participants from the Border Health Research Cohort, all treated with semaglutide ^[1].